These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 34189746)

  • 1. Mucopolysaccharidoses type I gene therapy.
    Hurt SC; Dickson PI; Curiel DT
    J Inherit Metab Dis; 2021 Sep; 44(5):1088-1098. PubMed ID: 34189746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of metabolic, craniofacial, and neurologic abnormalities in MPS I mice treated at birth with adeno-associated virus vector transducing the human alpha-L-iduronidase gene.
    Hartung SD; Frandsen JL; Pan D; Koniar BL; Graupman P; Gunther R; Low WC; Whitley CB; McIvor RS
    Mol Ther; 2004 Jun; 9(6):866-75. PubMed ID: 15194053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Highly Efficacious PS Gene Editing System Corrects Metabolic and Neurological Complications of Mucopolysaccharidosis Type I.
    Ou L; Przybilla MJ; Ahlat O; Kim S; Overn P; Jarnes J; O'Sullivan MG; Whitley CB
    Mol Ther; 2020 Jun; 28(6):1442-1454. PubMed ID: 32278382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal administration of AAV vectors for the treatment of lysosomal storage in the brains of MPS I mice.
    Watson G; Bastacky J; Belichenko P; Buddhikot M; Jungles S; Vellard M; Mobley WC; Kakkis E
    Gene Ther; 2006 Jun; 13(11):917-25. PubMed ID: 16482204
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neonatal nonviral gene editing with the CRISPR/Cas9 system improves some cardiovascular, respiratory, and bone disease features of the mucopolysaccharidosis I phenotype in mice.
    Schuh RS; Gonzalez EA; Tavares AMV; Seolin BG; Elias LS; Vera LNP; Kubaski F; Poletto E; Giugliani R; Teixeira HF; Matte U; Baldo G
    Gene Ther; 2020 Feb; 27(1-2):74-84. PubMed ID: 31827259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I.
    Osborn MJ; McElmurry RT; Lees CJ; DeFeo AP; Chen ZY; Kay MA; Naldini L; Freeman G; Tolar J; Blazar BR
    Mol Ther; 2011 Mar; 19(3):450-60. PubMed ID: 21081900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of Endovascular and Intraventricular Gene Therapy With Adeno-Associated Virus-α-L-Iduronidase for Hurler Disease.
    Janson CG; Romanova LG; Leone P; Nan Z; Belur L; McIvor RS; Low WC
    Neurosurgery; 2014 Jan; 74(1):99-111. PubMed ID: 24077583
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CRISPR-Cas9-mediated gene editing in human MPS I fibroblasts.
    de Carvalho TG; Schuh R; Pasqualim G; Pellenz FM; Filippi-Chiela EC; Giugliani R; Baldo G; Matte U
    Gene; 2018 Dec; 678():33-37. PubMed ID: 30081189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intranasal Adeno-Associated Virus Mediated Gene Delivery and Expression of Human Iduronidase in the Central Nervous System: A Noninvasive and Effective Approach for Prevention of Neurologic Disease in Mucopolysaccharidosis Type I.
    Belur LR; Temme A; Podetz-Pedersen KM; Riedl M; Vulchanova L; Robinson N; Hanson LR; Kozarsky KF; Orchard PJ; Frey WH; Low WC; McIvor RS
    Hum Gene Ther; 2017 Jul; 28(7):576-587. PubMed ID: 28462595
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neonatal Systemic AAV Induces Tolerance to CNS Gene Therapy in MPS I Dogs and Nonhuman Primates.
    Hinderer C; Bell P; Louboutin JP; Zhu Y; Yu H; Lin G; Choa R; Gurda BL; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Tarantal AF; Casal ML; Haskins ME; Wilson JM
    Mol Ther; 2015 Aug; 23(8):1298-1307. PubMed ID: 26022732
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enzymatic correction and cross-correction of mucopolysaccharidosis type I fibroblasts by adeno-associated virus-mediated transduction of the alpha-L-iduronidase gene.
    Hartung SD; Reddy RG; Whitley CB; McIvor RS
    Hum Gene Ther; 1999 Sep; 10(13):2163-72. PubMed ID: 10498248
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intrastromal Gene Therapy Prevents and Reverses Advanced Corneal Clouding in a Canine Model of Mucopolysaccharidosis I.
    Miyadera K; Conatser L; Llanga TA; Carlin K; O'Donnell P; Bagel J; Song L; Kurtzberg J; Samulski RJ; Gilger B; Hirsch ML
    Mol Ther; 2020 Jun; 28(6):1455-1463. PubMed ID: 32330426
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gene editing of MPS I human fibroblasts by co-delivery of a CRISPR/Cas9 plasmid and a donor oligonucleotide using nanoemulsions as nonviral carriers.
    Schuh RS; de Carvalho TG; Giugliani R; Matte U; Baldo G; Teixeira HF
    Eur J Pharm Biopharm; 2018 Jan; 122():158-166. PubMed ID: 29122734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. AAV Gene Therapy for MPS1-associated Corneal Blindness.
    Vance M; Llanga T; Bennett W; Woodard K; Murlidharan G; Chungfat N; Asokan A; Gilger B; Kurtzberg J; Samulski RJ; Hirsch ML
    Sci Rep; 2016 Feb; 6():22131. PubMed ID: 26899286
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safe and Sustained Expression of Human Iduronidase After Intrathecal Administration of Adeno-Associated Virus Serotype 9 in Infant Rhesus Monkeys.
    Hordeaux J; Hinderer C; Buza EL; Louboutin JP; Jahan T; Bell P; Chichester JA; Tarantal AF; Wilson JM
    Hum Gene Ther; 2019 Aug; 30(8):957-966. PubMed ID: 31017018
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vivo genome editing of mucopolysaccharidosis I mice using the CRISPR/Cas9 system.
    Schuh RS; Poletto É; Pasqualim G; Tavares AMV; Meyer FS; Gonzalez EA; Giugliani R; Matte U; Teixeira HF; Baldo G
    J Control Release; 2018 Oct; 288():23-33. PubMed ID: 30170069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model.
    Hinderer C; Bell P; Louboutin JP; Katz N; Zhu Y; Lin G; Choa R; Bagel J; O'Donnell P; Fitzgerald CA; Langan T; Wang P; Casal ML; Haskins ME; Wilson JM
    Mol Genet Metab; 2016 Sep; 119(1-2):124-30. PubMed ID: 27386755
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Liver-directed gene therapy corrects cardiovascular lesions in feline mucopolysaccharidosis type I.
    Hinderer C; Bell P; Gurda BL; Wang Q; Louboutin JP; Zhu Y; Bagel J; O'Donnell P; Sikora T; Ruane T; Wang P; Haskins ME; Wilson JM
    Proc Natl Acad Sci U S A; 2014 Oct; 111(41):14894-9. PubMed ID: 25267637
    [TBL] [Abstract][Full Text] [Related]  

  • 19. α- L-iduronidase gene-based therapy using the phiC31 system to treat mucopolysaccharidose type I mice.
    Stilhano RS; Martin PK; de Melo SM; Samoto VY; Peres GB; da Silva Michelacci YM; da Silva FH; Pereira VG; D'Almeida V; da Cruz AT; Jasiulionis MG; Han SW
    J Gene Med; 2015; 17(1-2):1-13. PubMed ID: 25597593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. ZFN-Mediated In Vivo Genome Editing Corrects Murine Hurler Syndrome.
    Ou L; DeKelver RC; Rohde M; Tom S; Radeke R; St Martin SJ; Santiago Y; Sproul S; Przybilla MJ; Koniar BL; Podetz-Pedersen KM; Laoharawee K; Cooksley RD; Meyer KE; Holmes MC; McIvor RS; Wechsler T; Whitley CB
    Mol Ther; 2019 Jan; 27(1):178-187. PubMed ID: 30528089
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.